EichorEICHOR
Location: Fairway Synced from ClinicalTrials.gov · August 09, 2026

Clinical studies recruiting near Fairway

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias
Phase 1/Phase 2 · The University of Kansas Hospital · Lin BioScience, Inc · NCT05756322MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Wi
Phase 2 · University of Kansas Clinical Research Center · National Cancer Institute (NCI) · NCT05564390A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Phase 1 · The University of Kansas - Clinical Research Center · Pfizer · NCT07206225Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally A
Phase 1/Phase 2 · University of Kansas Clinical Research Center · National Cancer Institute (NCI) · NCT04172532Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astr
Phase 1 · University of Kansas Clinical Research Center · National Cancer Institute (NCI) · NCT06860594Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
Phase 1/Phase 2 · University of Kansas Clinical Research Center · Beat AML, LLC · NCT03013998A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathie
Phase 3 · KU Clinical Research Center - Clinical and Translational Sci · Pfizer · NCT05895786Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM
Phase 2 · University of Kansas Clinical Research Center · SWOG Cancer Research Network · NCT06769126A Study of IBI363 in Subjects with Advanced Solid Malignancies
Phase 2 · University of Kansas Medical Center (KUMC) · Innovent Biologics (Suzhou) Co. Ltd. · NCT06281678A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax,
Phase 1 · The University of Kansas Medical Center Research Institute · Kura Oncology, Inc. · NCT05735184Nutrition OUtReach In Systems of Healthcare
NA · University of Kansas Cancer Center · University of Kansas Medical Center · NCT06802406A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
Phase 1/Phase 2 · Nkarta Investigational Site · Nkarta, Inc. · NCT06733935A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injectio
Phase 1 · GSK Investigational Site · GlaxoSmithKline · NCT06431594Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NI
Phase 1 · University of Kansas Clinical Research Center · National Cancer Institute (NCI) · NCT03816345An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Phase 3 · Research Site · AstraZeneca · NCT05952557Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
Phase 3 · A20 · Cartesian Therapeutics · NCT06799247A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular
Phase 1 · The University of Kansas Cancer Center, Investigational Drug · Pfizer · NCT03460977Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidin
Phase 2 · University of Kansas Clinical Research Center · National Cancer Institute (NCI) · NCT05554393A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Phase 1 · The University of Kansas Cancer Center, Investigational Drug · Seagen, a wholly owned subsidiary of Pfizer · NCT04389632Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior T
EARLY_Phase 1 · The University of Kansas Cancer Center · University of Kansas Medical Center · NCT06414681Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin
Phase 2 · University of Kansas Clinical Research Center · National Cancer Institute (NCI) · NCT06917911ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies
Phase 1 · Kansas University Cancer Center · Changchun Intellicrown Pharmaceutical Co. LTD · NCT04412616Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
NA · University of Kansas Clinical Research Center · NRG Oncology · NCT05080673Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
Phase 1/Phase 2 · The University of Kansas Cancer Center (KUCC) · University of Kansas Medical Center · NCT04467723Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer
Phase 2 · The University of Kansas Cancer Center (KUCC) · University of Kansas Medical Center · NCT07220135Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
Phase 1/Phase 2 · University of Kansas Clinical Research Center · National Cancer Institute (NCI) · NCT07069699Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Trea
Phase 2 · University of Kansas Clinical Research Center · National Cancer Institute (NCI) · NCT06317649Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had
Phase 2/Phase 3 · University of Kansas Clinical Research Center · SWOG Cancer Research Network · NCT06616584DMCRN-02-001: Assessing Pediatric Endpoints in DM1
Phase N/A · University of Kansas Medical Center · Virginia Commonwealth University · NCT05224778A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
Phase 3 · University of Kansas Hospital · Novartis Pharmaceuticals · NCT07326709
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.